Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE1
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Status
- RECRUITING
- Phase
- PHASE3
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE1
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
- Status
- RECRUITING
- Phase
- PHASE2
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Epco, Zanu, Ritux for R/R FL or MZL
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2